US Patent Issued to Antlera Therapeutics on April 14 for "Method of screening for compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene" (Canadian Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,785, issued on April 14, was assigned to Antlera Therapeutics Inc. (Foster City, Calif.).

"Method of screening for compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene" was invented by Guohua Pan (Oakville, Canada), Jason Moffat (Toronto), Sachdev Sidhu (Toronto), Stephane Angers (Mississauga, Canada), Zachary Steinhart (Toronto) and Xiaowei Wang (Toronto).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression of activity of Frizzled...